Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study.

North County Endocrine Medical Group, Escondido, California, USA.
Diabetes Technology &amp Therapeutics (Impact Factor: 2.29). 06/2007; 9(3):203-10. DOI: 10.1089/dia.2007.0205
Source: PubMed

ABSTRACT Real-time continuous glucose monitoring (CGM) was studied in 140 adults with diabetes over a 12-week period of home use. Hemoglobin A(1c)(HbA1c) was measured on day 1 (baseline) and at weeks 6 and 12.
On day 1, participants received the CGM device (STS(R) System, DexCom, Inc., San Diego, CA) and underwent training on proper use. Insertion of the first sensor was performed under staff supervision. Subjects inserted subsequent sensors on their own. After calibration, the device (a 3-day sensor, receiver, and transmitter) provided users with real-time glucose values updated at 5-min intervals, glucose trend graphs, configurable high/low alerts, and a hypoglycemia alarm (<or=55 mg/dL). Study participants were given supplies sufficient for 3 weeks of device use. Follow-up visits were performed at 3-week intervals for resupply and to download CGM data, with a final visit at the end of week 12.
Overall, a reduction in HbA1c of 0.4 +/- 0.05% (least squares mean +/- SE) was observed, P < 0.0001. Significant HbA1c reductions were observed across subgroups of subjects with both type 1 and 2 diabetes, and those delivering insulin by multiple daily injections and pumps. The largest HbA1c reduction (1.4 +/- 0.4%) was observed in subjects with baseline HbA1c >9.0%. Increased CGM use was associated with greater reductions in HbA1c.
This observational study showed that home use of real-time GCM was safe and well tolerated and associated with a clinically and statistically significant reduction in HbA1c. Large-scale randomized, controlled outcome studies of CGM are indicated.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Little information is available on personal real-time continuous glucose monitoring (PCGM) in patients ≥65 years old. We report on PCGM use in insulin-requiring patients age ≥65 in a community endocrine practice.Methods: Patients ≥65 or older who had been prescribed PCGM were identified by retrospective review. A1C values from the year prior and subsequent to PCGM prescription, most recent A1C, continued PCGM usage, percent reporting severe hypoglycemia (SH), and rate of SH were examined.Results: Thirty-eight patients were identified: 31 with type 1 diabetes, 21 female, age 70 years (range 65-78), diabetes duration 31 years. Twenty-eight were on insulin pump therapy, 29 were using PCGM regularly and 25 had both pre- and post-PCGM use A1C results. Regular PCGM use was associated with a decrease in mean (SD) A1C: 7.6(0.9)% to 7.1(0.9)%, (p<0.0001), maintained until the most recent A1C (7.2[0.8]%, p=0.0145, average 37 months), with fewer reporting SH (from 79% to 31%, p=0.0002), and lower rate of SH (0.37 to 0.12 per year, p=0.0007). The group of 9 patients who did not continue PCGM (mean use 3 months) was too small to allow meaningful statistical evaluation. Lack of insurance coverage was the most common reason given for not using/continuing PCGM. Those continuing PCGM were more likely to have insurance coverage for PCGM (86%) than those not continuing PCGM (25%).Conclusions: Patients ≥65 with insulin-requiring diabetes achieve improved glycemic control with regular use of PCGM. The presence of PCGM insurance coverage favored continued PCGM use.
    Endocrine Practice 08/2014; 1(-1):1-21. DOI:10.4158/EP14017.OR · 2.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Highlights ► 12 diabetic patients were monitored simultaneously with 2 commercial CGM. ► Analysis and comparison of postprandial error of the devices was performed. ► Delay, stationarity, probability distribution and correlations were modeled. ► High variability and non-stationarity of the error was observed. ► Simulation models were built for its use in in silico studies.
    Biomedical Signal Processing and Control 03/2014; 10:322–331. DOI:10.1016/j.bspc.2012.12.003 · 1.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To estimate the frequency of continuous glucose monitoring (CGM) use and change in HbA1c compared to self-monitoring of blood glucose (SMBG) alone in adults with type 1 diabetes in a clinical practice setting.Methods: We retrospectively identified 66 adult type 1 diabetes patients at the Barbara Davis Center for Diabetes who first initiated CGM from 2006 to 2011 and 67 controls using SMBG. Frequency of CGM use was estimated from survey recall and defined as average number of days/month of CGM use during a maximum follow-up of 10 months. Change in HbA1c was calculated as the difference between the baseline value and lowest follow-up value.Results: Mean change in HbA1c for CGM users was -0.48% (95% CI: -0.67, -0.28), and for SMBG users was -0.37% (95% CI: -0.56, -0.18). The between group mean difference in change in HbA1c, adjusted for patient characteristics, was -0.11% (95% CI: -0.38, 0.16), whereas the subgroup with a baseline HbA1c ≥ 7.0% and users of CGM ≥ 21 days/month was -0.36% (95% CI: -0.78, 0.05). Nearly half (N=32, 48%) used CGM < 21 days/month. Reasons for low frequency of CGM use or discontinuation included sensor costs, frequency of alarms, inaccuracy, and discomfort.Conclusions: These CGM data from clinical practice suggest a trend towards decreasing HbA1c for adults with type 1 diabetes, especially in patients with higher baseline HbA1c and higher frequency of CGM use. Future studies are needed on the use of CGM in larger populations of clinical practice adult type 1 diabetes patients.
    Endocrine Practice 05/2014; 20(10):1-23. DOI:10.4158/EP14027.OR · 2.59 Impact Factor


Available from